Cardiol Therapeutics to prioritize its Phase II clinical programs focused on developing CardiolRx for two underserved diseases affecting the heartProactive Investors • 10/25/22
Cardiol Therapeutics says to prioritize its Phase II clinical programs focused on developing CardiolRx for two underserved diseases affecting the heartProactive Investors • 10/25/22
Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart DiseasesNewsfile Corp • 10/25/22
Cardiol Therapeutics unveils new preclinical study results providing evidence of cardioprotective properties of CardiolRxProactive Investors • 10/03/22
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac FibrosisNewsfile Corp • 10/03/22
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of AmericaNewsfile Corp • 09/28/22
Cardiol Therapeutics says first patient enrolled in acute myocarditis trial of its oral cannabinoid formulation CardiolRxProactive Investors • 08/03/22
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute MyocarditisNewsfile Corp • 08/03/22
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDTNewsfile Corp • 06/27/22
Cardiol Therapeutics appoints Teri Loxam and CFO Chris Waddick to its board of directorsProactive Investors • 05/19/22
Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of DirectorsNewsfile Corp • 05/19/22
Cardiol Therapeutics receives US FDA authorization for Phase II study of CardiolRx for recurrent pericarditisProactive Investors • 05/17/22
Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent PericarditisNewsfile Corp • 05/17/22
Cardiol Therapeutics looks ahead to busy 2022 as it advances new treatment options for cardiovascular diseaseProactive Investors • 03/24/22
Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease SummitNewsfile Corp • 03/22/22
Cardiol Therapeutics says Jennifer M. Chao has been appointed as director of the companyProactive Investors • 03/15/22
Cardiol Therapeutics receives clearance to expand eligible patient group for its LANCER studyProactive Investors • 03/01/22
Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER TrialNewsfile Corp • 03/01/22
Cardiol Therapeutics appoints three new members to its Scientific Advisory BoardProactive Investors • 01/19/22
Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory BoardNewsfile Corp • 01/19/22